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Summary 
Background: Patients with type 2 diabetes have a 2-4 fold increased risk of mortality from 
cardiovascular disease compared to age-matched non-diabetic subjects. This is mainly due to 
premature atherosclerosis which in part can be accounted for by hyperglycaemia. Early 
events in human atherosclerosis occur in the intima of the vascular epithelia. Macrophages 
are the most prominent cell type in atherosclerotic lesions, and uptake of oxidised LDL and 
accumulation of cholesterol esters in monocyte/macrophages (foam cell formation) is an 
important early event in atherosclerosis. Previous work in J774.2 murine macrophages 
exposed to hyperglycaemia in combination with insulin or leptin, show that the rate of 
cholesterol ester deposition significantly increased through down-regulation of hormone-
sensitive lipase (HSL) and up-regulation of acyl-CoA-cholesterol acyltransferase (ACAT). 
The transcriptional repressor Id2 has the capability to suppress HSL promoter activity, and 
in J774.2 macrophages Id2 is up-regulated by hyperglycaemia via the hexosamine signalling 
pathway, involving the rate-limiting enzyme, GFAT, and the enzyme responsible for O-
linked glycosylation of proteins, OGT, indicating a direct role of Id2 in macrophage foam 
cell formation. The role of hyperglycaemia and the hexosamine signalling pathway in 
primary human macrophages has never been established. 
Methods: Peripheral blood mononuclear cells (PBMC) from healthy donors were 
differentiated for 7 days into macrophages. The macrophages were cultured for different 
times under normoglycaemic (5 mM) or hyperglycaemic conditions (20 mM) or in the 
absence or presence of glucosamine, PUGNAc or fructose at 5 mM glucose. Cells were 
lysed in RIPA buffer and protein samples were separated by SDS-PAGE.  GFAT, OGT, Id1 
and Id2 protein expression as well as abundance of O-GlcNAcylated proteins were 
determined by Western blotting, and subcellular localization of OGT, O-GlcNAcylation and 
Id2 was studied by immunoflouresence. 
Results: Fructose and glucosamine induce Id1 and Id2 protein expression as well as the 
abundance of O-GlcNAclated proteins in primary human macrophages. Moreover, in 
accordance with previous observations in the J774.2 murine macrophages cell line, Id2 was 
found to be a target for O-linked glycosylation in primary human macrophages. 
Furthermore, we demonstrated nucleo-cytoplasmic shuttling of Id2 and OGT by high 
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glucose, but in contrast to observations in J774.2 cells, hyperglycaemia has no effect on the 
protein levels of Id1 and Id2. Finally, hyperglycaemia did not regulate GFAT and OGT 
protein levels in primary human macrophages. 
Conclusion: In resting human macrophages, the hexosamine signalling pathway is involved 
in the up-regulation of Id1 and Id2 protein, but hyperglycaemia is not able to increase flux 
through the hexosamine signalling pathway as compared to murine macrophages and does 
not regulate GFAT and OGT protein levels. 
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1. Introduction 
1.1 General introduction 
The consumption of refined sugar has increased considerably during the past several 
decades. Because it primarily consists of empty calories, replacing more nutritious foods 
with sugar decreases the intake of vitamins, minerals, essential fatty acids and other 
beneficial nutrients (1). Refined sugar, sucrose, is hydrolysed by sucrase in the small 
intestine to fructose and glucose (2), and even if the body has an obligatory requirement for 
glucose, determined largely by the demands of the brain, high blood glucose levels are 
associated with both immediate and long-term consequences. For these reasons blood 
glucose concentration is tightly regulated by homeostatic regulatory systems including 
insulin secretion stimulated by hyperglycaemia and secretion of counter regulatory 
hormones like glucagon, epinephrine, cortisol and growth hormones to restore 
normoglycaemia. The rapid absorption of glucose following consumption of refined sugars 
and high glycemic index meals challenges these homostatic mechanisms. The acute repeated 
hyperglycaemia as well as long-term hyperglycaemia may cause overeating, obesity, insulin 
resistance and eventually type 2 diabetes and atherosclerosis (3).  
The deleterious effects of type 2 diabetes are mainly due to the development of vascular 
pathology in the retina, renal glomerulus, peripheral nerve and arteries that supply the heart, 
brain and lower extremities (4). The fact that hyperglycaemia is the main cause of 
microvascular events is well-known, and the mechanisms by which they occur, are thourghly 
studied (5, 6). Based on epidemiological studies, hyperglycaemia alone is also a risk factor 
for cardiovascular disease in patients with diabetes, but the molecular mechanisms of 
accelerated clotting of arteries that result from diabetes-associated hyperglycaemia, are still 
not fully understood (7). 
Fructose, compared to glucose or sucrose, results in significantly lower insulin responses 
and serum glucose levels, and when used in moderation, fructose is a safe or even desirable 
sweetener for patients with diabetes (1). However, the adverse effects of fructose on other 
aspects of metabolism, like glycosylation of tissue proteins, intracellular accumulation of 
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sorbitol and oxidative stress might counterbalance its influence on glycaemic control (1). 
Fructose is transported by the facilitative glucose transporter 5 (Glut 5) that unlike other 
members of this family (Glut 1-4) is a very poor transporter of glucose and appears to 
function as a fructose transporter (8). Interestingly, previous studies have shown that Glut 5 
is strongly up regulated in macrophages during differentiation, suggesting that these cells 
become extremely sensitive to increased fructose level (8). The main pathway for fructose 
metabolism is in the liver, due to the presence of the enzyme fructokinase (2). However, 
increasing serum fructose concentration results in the conversion of fructose to fructose-6-
phosphate by hexokinase in extra-hepatic organs (1) suggesting that fructose, at least in part, 
is able to mimic the deleterious effects of hyperglycaemia.  
1.2 Hyperglyceamia  
Hyperglycaemia is defined as a condition where plasma glucose level exceeds the normal 
range of 3-7 mmol/l (9, 10). In healthy individuals normoglycaemia is restored by the action 
of insulin, but without sufficient insulin, caused by partial or total failure of the pancreatic 
insulin production (type 1 diabetes) or insuffient insulin production or resistance to its action 
(type 2 diabetes) long-term hyperglycaemia is obtained (9). Hyperglycaemic damage is 
thought to be mediated by four different pathways: The polyol pathway, the protein kinase-C 
(PKC) pathway, the AGE (Advanced Glycated Endproducts) pathway and the hexosamine 
pathway (4) (Figure 1.1) Hyperglycaemia increases oxidative stress caused by 
overproduction of superoxide, and it is suggested that this plays a role in the activation of 
these four pathways (4).    
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Fig.1.1 Potential mechanism by which hyperglycaemia activates four pathways of 
hyperglycaemic damage. Increased flux of glyceraldehyde-3-P to DAG, an activator of PKC, and of 
triose phosphates to methylglyoxal, the main intracellular AGE precursor. Increased flux of fructose-
6-phosphate to UDP-N-acetylglucosamine increases modification of proteins by O-linked N-
acetylglucosamine (O-GlcNAc) and increased glucose flux through the polyol pathway consumes 
NADPH and depletes GSH. (Figure is adapted from Brownlee, 2001 (4)). 
1.2.1 Increased polyol pathway flux 
The polyol pathway leads to increased intracellular oxidative stress by reducing the amount 
of the intracellular antioxidant, reduced glutathione (4). The enzyme aldose reductase 
catalyzes the reduction of glucose to sorbitol using nicotinamid adenine dinucleotide 
phosphate (NADPH) as cofactor (11, 12). The activity of aldose reductase increases under 
hyperglycaemic conditions, resulting in consumption of NADPH (4). The recycling of the 
antioxidant glutathion depends on NADPH supplies, and depletion of these supplies results 
in intracellular oxidative stress (4, 13, 14). Another reaction that uses NADPH is the 
synthesis of nitrogen oxide (NO), and if the production of NO is decreased, vasoconstriction 
and poor blood supply are promoted (15, 16). Additionally, the harmful effects of sorbitol, 
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includes eye diseases caused by osmotic stress (17) as well as changes in signal transduction 
and gene expression (18).  
1.2.2 Activation of protein kinase C 
Hyperglycaemia can mediate its harmful effects by increasing the synthesis of diacylglycerol 
(DAG), an important activator of α, β, and δ protein kinase-C (PKC), a family of serine- 
threonine kinases (17). PKC is suggested to play a key role in intracellular signal 
transduction downstream of hormones (19), and changes in the DAG-PKC pathway can 
cause alterations in regulatory pathways resulting in functional changes in vascular tissues, 
leading to endothelial dysfunction (13). 
1.2.3 Advanced Glycated End products 
In the AGE pathway proteins, lipids and nucleic acids are irreversibly modified by sugar and 
lipids (20, 21). This nonenzymatic process is initiated by the reaction between a free amino 
group on a protein or a fatty acid and a carbonyl group on a reduced sugar (22). AGEs were 
originally thought to arise from reactions between extracellular proteins and glucose, but it is 
now believed that intracellular hyperglycaemia is the primary event in the formation of both 
intracellular and extracellular AGEs (4). Reversible Schiff-bases are formed and further 
transformed into Amadori products, which rearranges to the highly reactive AGE precursors 
such as glyoxals, methylglyoxals and 3-deoxyglucosone which react with amino groups and 
lead to the formation of AGE (22). Additionally, AGEs can be formed from other 
carbohydrates like fructose, ribose or glyceraldehyde or from auto-oxidative glycation (23). 
Intracellular AGE precursors are able to modify intracellular proteins, including 
transcription factors, leading to altered cellular functions. Furthermore, AGE precursors may 
diffuse out of the cell and modify extracellular matrix components. These modified proteins 
interact abnormally with other matrix components and integrins on cells, and cause cellular 
dysfunction. Additionally, plasma proteins modified by AGE precursors bind to AGE 
receptors (RAGEs) on macrophages, endothelial cells and mesangial cells, and this ligation 
has been shown to activate nuclear factor κB (NF-κB) causing pathological changes in gene 
expression (4). 
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1.3 The hexosamine signalling pathway  
Up to 99 % of intracellular glucose is destined to glycolysis and glycogen storage, but a 
small fraction (1-5 %) is diverted to the hexosamine pathway (24). This pathway is currently 
envisioned to consist of two parts; synthesis of uridine diphosphate (UDP) –N-
acetylglucosamine (UDP-GlcNAc) and transfer and removal of O-GlcNAc (25). The 
precursors of the synthesis of UDP-GlcNAc include the amino acid glutamine, lipid derived 
acetyl-coenzyme A (CoA), glucose and uridine (25) The first part of the pathway is initiated 
by the conversion of fructose-6-phosphate to glucosamine-6-phosphate by the rate limiting 
enzyme L-glutamine:D-fructose-6-phosphate amidotransferase (GFAT) and culminates in 
UDP-GlcNAc formation (26, 27, 28). One of the roles of UDP-GlcNAc is to serve as a 
precursor for the essential formation of complex membranous and secretory glycoproteins in 
the endoplasmatic reticulum and Golgi apparatus (29, 30), and the hexosamine pathway was 
previously thought to be entirely a biosynthetic pathway. In 1991, however, new insights 
into the functional roles of this pathway were obtained (31). Incubation of isolated 
adipocytes under hyperglycaemic conditions enhanced the flux through the hexosamine 
pathway and culminated in a state of cellular insulin resistance (31). Insulin resistance is 
defined as the inhibition of intracellular signal molecules mediating insulin effects, such as 
glucose transport (9). It occurred that the hexosamine pathway contained a nutrient sensing 
and metabolic signalling ‘arm’, responsible for desensitizing of the glucose transport system. 
With this realization, the name ‘Hexosamine signalling pathway’ was proposed (32), a name 
which from now on is adapted in this particular study. The metabolic effects of this pathway 
are mediated by O-GlcNAcylation on serine and threonine residues on regulatory proteins, 
using UDP-GlcNAc as substrate (33, 34) (Figure 1.2). In insulin responsive tissues, like 
adipose tissue and skeletal muscle, insulin signalling results in facilitative Glut 4 
translocation to the cell membrane followed by glucose uptake, and this is dependent on 
activation of phosphatidyl inosityl–3- kinase (PI3-K). (35). In models of type II diabetes, the 
recruitment of Glut 4 is insufficient, and this is postulated to be caused by a specific defect 
in PI3-K signalling (36). Also, PI3-K has been shown to be a target for O-linked 
glycosylation (25). To elucidate the role of the hexosamine signalling pathway and O-
GlcNAcylation in macrophage foam cell formation in atherosclerosis, one specific aim 
of this study is to investigate whether high glucose via the hexosamine signalling 
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pathway increases the abundance of O-GlcNAcylated proteins in primary human 
macrophages. 
 
Fig.1.2 The hexosamine signalling pathway. This pathway consists of two parts; synthesis of 
uridine diphosphate (UDP) – N-acetylglucosamine (UDP-GlcNAc), initiated by the conversion of 
fructose-6-phosphate (F-6-P) to glucosamine-6-phosphate (glucosamine-6-P) by the rate limiting 
enzyme L-glutamine:D-fructose-6-phosphate amidotransferase (GFAT), and transfer and removal of 
O-GlcNAc. (6-diazo-5-oxo-norleucine) DON and azaserine inhibit the enzymatic activity of GFAT. 
UDP-GlcNAc is precursor for formation of complex membranous and secretory glycoproteins and 
substrate for O-linked glycosylation (O-GlcNAc). The enzymes OGT and OGA catalyze the turnover 
of O-GlcNAc, and the enzymatic activity of OGA can be inhibited by O-(2-acetaminido-2-deoxy-D-
glucopyranosylidine) amino-N-phenylcarbamate (PUGNAc). Hyperglycemia and glucosamine 
increase the flux through the hexosamine biosynthetic pathway, leading to an increase in the 
abundance of O-GlcNAc modifications. As serum concentration of fructose increases, fructose is 
converted to fructose-6-phosphate by hexokinase in extra-hepatic organs, and is also likely to 
increase the flux through this pathway. O-GlcNAc modifications lead to functional changes in target 
proteins (such as the transcriptional repressor Id2) and can affect transcription, translation and 
signalling.  
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1.3.1 GFAT 
The rate-limiting enzyme of the hexosamine signalling pathway is L-glutamine:D-fructose-
6-phosphate amidotransferase (GFAT) (26, 27, 28). GFAT is a 681 amino-acid protein with 
a molecular weight of approximately 77 kDa (28) and composed of two domains: a 
glutaminase domain, which catalyzes the hydrolysis of glutamine to glutamate and ammonia, 
and a synthase domain, which catalyzes the amination and isomerization of fructose-6-
phosphate to glucosamine-6-phosphate (37). As GFAT is rate limiting in the synthesis of 
glucosamine, the main substrate for protein glycosylation, the quantity and activity of this 
enzyme is critical for the essential glycoprotein synthesis in eucaryotic cells (38). There are 
two isozymes of GFAT; GFAT1 and GFAT2. They are encoded by different genes and their 
relative expression varies among tissues; GFAT1 is ubiquitous with high levels of 
expression of protein and mRNA in adipocytes and skeletal muscle, and a marked, but 
varying expression in vascular smooth muscle cells (39). GFAT2 is preferentially expressed 
throughout the central nervous system, especially in the spinal cord (40).  
Several studies show that GFAT is under very tight regulation (38, 39). In adipocytes the 
enzyme activity is inhibited by glucose and insulin (41, 42), and in all eukaryotes, UDP-
GlcNAc allosterically inhibits the activity (28, 43). Additionally, phosphorylation by cAMP-
dependent protein kinase A (PKA) appears to act as a modulator of GFAT activity (27). 
However, expression of GFAT protein in skeletal muscle seem to be increased when plasma 
concentration of the saturated fatty acids palmitate and stearate are high (44). The fact that 
GFAT is highly expressed in most tissues involved in the development of diabetic late 
complications indicates that GFAT expression may be induced by manifest diabetes (39). 
GFAT protein expression in primary human macrophages has not previously been 
studied, and one particular aim of this study is to investigate whether high levels of 
glucose, via the hexosamine signalling pathway, affects GFAT protein expression. 
1.3.2 O-linked glycosylation, OGT and OGA 
O-linked glycosylation of serine and threonine residues of various regulatory proteins is a 
reversible protein modification (45). O-GlcNac is ubiquitous and essential, and so far, more 
than 500 proteins, involved in almost all aspects of cellular processes, have been identified 
to be O-GlcNAcylated (24, 25, 46). Unlike the static nature of extra cellular glycosylation, 
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O-GlcNAc cycles dynamically in response to the extracelullar environment (35). O-
GlcNAcylation appears to be as abundant as phosphorylation (33, 34), and occurs both 
simultaneously and reciprocally to phosphorylation (47) (Figure 1.3). There is a complex 
and dynamic interplay between O-GlcNAc and O-phosphate, and the combination of 
modifications creates enormous molecular diversity to fine tune protein interactions and 
functions (48). Concentrations of the substrate for O-GlcNAcylation, UDP-GlcNAc, are 
highly sensitive to fluxes in nutrients, energy and metabolic nitrogen, and rapid changes in 
UDP-GlcNAc concentration serves as a sensor by directly affecting the extent of O-
GlcNAcylation and thus, phosphorylation of regulatory proteins (48). The enzymes 
catalyzing the addition and removal of O-GlcNAc has been characterized, and unlike protein 
phosphorylation in which approximately 650 enzymes are involved in the regulation, only 
two catalytic enzymes, OGT and OGA, catalyze the turnover of O-GlcNAc (35).  
OGT 
The enzyme responsible for the transfer of UDP-GlcNAc to serine and threonine protein 
residues is O-linked N-acetylglucosaminyl (O-GlcNAc) transferase (OGT) (45). OGT is a 
heterotrimer composed of two catalytic 110-kDa subunits and one regulatory 78-kDa subunit 
(49). The molecule is encoded by a single gene on the X chromosome (45), and gene knock-
out experiments have shown that OGT is essential for stem cell viability and embryonic 
development (50). OGT consists of an N-terminal segment with targeting information, a 
tetratrcopeptide repeat (TPR) domain, a linker region and a C-terminal highly conserved 
catalytic domain (25). TPRs are 34-amino acid repeats that facilitate protein-protein 
interactions (25). The OGT isoforms contain between 1 to more than 16 TPRs, and varying 
the number of TPR domains affect the substrate recognition, trimerization  (51) and cellular 
localization (45, 52, 53) of the enzyme. In mammalian cells two transcripts are well 
characterized; nucleocytoplasmic OGT (ncOGT) and mitochondrial OGT (mOGT) (34, 54, 
55). As OGT seem to be predominantly located in the nucleus, the nucleocytoplasmic OGT 
(ncOGT) is the most thoroughly studied of the known splice variants (34). OGT is subject to 
autoglycosylation and tyrosine phosphorylation (56), suggesting that these post-translational 
modifications are regulators of the enzymatic activity. Furthermore, the concentration of 
UDP-GlcNAc, which increases in response to hyperglycaemia, has also been shown to play 
a key role in modulating the activity of OGT (35). The Km of OGT for different substrates 
changes at different UDP-GlcNAc concentrations (57), and as UDP-GlcNAc rapidly changes 
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in concentration in response to nutrients and environmental factors, OGT is able to sense 
these changes and in turn, transduce this information to protein regulatory networks (46). In 
liver cells, insulin stimulates the synthesis of OGT and enhances cytosolic staining of OGT 
(58). The OGT protein expression in primary human macrophages has not yet been 
studied. One specific aim of the current study is to study the subcellular distribution of 
OGT as well as the regulation of OGT protein expression by high glucose and the 
hexosamine signalling pathway. 
OGA 
Removal of O-GlcNAc is performed by a ubiquitous, nuclear/cytosolic β-N-
acetylglucosaminidase called O-GlcNAcase (OGA) (50). This is a 917 amino-acid 
heterodimer composed of a 54-kDa α-subunit and a 51-kDa β-subunit. (50, 59, 60, 61). The 
enzymatic activity of OGA can be inhibited by O-(2-acetaminido-2-deoxy-D-
glucopyranosylidine) amino-N-phenylcarbamate (PUGNAc). PUGNAc is an O-GlcNAc 
analogue that prevents cycling of O-GlcNAc on proteins without significantly altering N-
linked glycosylation or UDP-GlcNAc levels (63).  OGT and OGA are strongly associated 
into a single complex (64). Experiments in transgenic mice have shown that this complex is 
essential for proper estragon dependent cell signalling as well as mammary development 
(64). Furthermore, these enzymes are components of several multiple factor holoenzyme 
complexes which appear to regulate both the targeting and 
activity of O-GlcNAc cycling (45, 52, 53, 65, 66). 
Fig.1.3 There is a complex and dynamic interplay between 
O-GlcNAc and O-phosphate. On some proteins O-GlcNAc 
and O-phosphate compete dynamically for the same serine or 
threonine hydroxyl moiety. This reciprocal occupancy seems to 
produce different activities or stability in the proteins (a). In 
certain proteins, O-GlcNAc and O-phosphate can occur next to 
each other. Adjacent occupancy by each modification 
reciprocally influences the functions or turnover of proteins (b) 
(Figure is adapted from Hart et al., 2007 (48)).  
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O-GlcNAcylated proteins 
Several cytosolic and nuclear proteins have been identified as targets for O-GlcNAylation 
including kinases, phosphatases, transcription factors, metabolic enzymes, chaperones and 
cytoskeletal proteins (25). The O-linked glycosylated nuclear pore protein p62 is crucial for 
the nuclear pore complex (NPC) formation and directly involved in the nuclear transport 
process (67). Furthermore, O-GlcNAc modification of the 26S proteasome prevents 
proteolysis of ubiquitinylated transcription factors like Sp1 by inhibiting the adenosine 
triphosphatease activity (ATPase) activity of the proteasome (68). Another example, in 
which O-GlcNAcylation inhibits substrate activity, is by inhibition of the enzyme eNOS 
(25). The Akt phosphorylation site of eNOS seems to be glycosylated instead of 
phosphorylated under hyperglycaemic conditions, and this O-GlcNAc modification and 
impairment of eNOS contributes to endothelial dysfunction in atherosclerosis (69).  
Furthermore, some cytosolic proteins need to be in their O-GlcNAc state to be transported to 
the nucleus. One of these proteins is Tau, which belongs to the family of brain microtubule-
associated proteins. Tau protein is O-linked glycosylated as well as phosphorylated, and it 
seems like the nuclear localisation is regulated by relative abundance of these two 
modifications. (70) 
Transcription factors make up most of the O-GlcNAc modified proteins (71). The first 
identified was Sp1, a regulator of several house keeping genes. It has multiple O-GlcNAc 
modification sites, and its phosphorylation on Ser/Thr is inversely proporsal to its O-
GlcNAC modification. (33). CMyc regulates gene transcription in cell proliferation, cell 
differentiation and programmed cell death, and both O-GlcNAcylation of Sp1 and cMyc 
increases their transactivating potential (47). O-GlcNAc modification also has a protective 
role during stress responses (25). Increased O-linked glycosylation of the tumour suppressor 
p53, in response to cellular stress, including DNA damage, is stabilizing the protein and 
increases its anti-proliferative activity (46, 47, 72). 
1.4 Inhibitor of DNA binding (Id) family 
Inhibitor of differentiation and DNA binding (Id) genes encode a family of 4 basic helix-
loop-helix (bHLH) proteins (Id1, Id2, Id3 and Id4) that lack the basic DNA binding domain 
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(73). Id proteins are able to act as transcriptional repressors by dimerizing with the class A 
bHLH transcription factors (E-proteins) and form non-functional heterodimers. Thus, Id 
proteins act as dominant-negative regulator of these transcription factors and have the 
capability to modulate a wide range of gene expression events in the cell (74, 75, 76). Id1, 
Id2 and Id3 are expressed ubiquitously, and Id4 is expressed predominantly in testis, brain 
and kidney. They act as positive regulators of cell proliferation, and their gene expression is 
highest in proliferating cells (73). Id mRNA concentrations rapidly increases in response to 
serum or growth factors, including insulin (77), and previous studies have shown that Id1 
protein is regulated by glucose (77) and fatty acids (78) in β-cells. Recently, in a murine cell 
line, Id2 protein expression was shown to be up-regulated by glucose (79). Furthermore, 
overexpression of GFAT in J774.2 macrophages increased Id2 protein levels, suggesting that 
the hexosamine signalling pathway is mediating the effect of high glucose on Id2 
(unpublished data). Id2 is targeted to proteasomal degradation through N-terminal 
ubiquitination by 26S (80), and O-GlcNAc modification of the 26S proteasome inhibits 
proteolysis through inhibition of the ATPase activity of the proteasome (68).  This may be a 
mechanism by which hyperglycaemia via the hexosamine signalling pathway increase Id2 
protein expression in macrophages. Moreover, experiments in J774.2 macrophages indicate 
that Id2 itself is a target for O-GlcNAcylation. This may lead to stabilization of the protein 
by making it less susceptible to proteasomal degradation (unpublished data). One aim of the 
current study is to verify the O-GlcNAcylation of Id2 in primary human macrophages.  
Experiments in hepatocytes show that overexpression of GFAT causes reduced hepatic 
gluconeogenesis compared to controls despite of lower fasting glucose and insulin levels 
(26). Furthermore, overexpression of Id2 in hepatocytes suppresses Dexametasone/cAMP-
induced activation of phosphoenolpyruvate carboxykinase (PEPCK) promoter causing 
inhibition of hepatic gluconeogenesis, suggesting a role for the hexosamine signalling 
pathway and Id2 in mediating the inhibiting effect of glucose on hepatic glucose production 
(unpublished data)(Figure 1.4).  
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Fig.1.4 Overexpression of Id inhibits Dexametasone/cAMP-mediated activation of PEPCK gene 
expression in H4IIE hepatoma cells. Overexpression of Id2 in hepatocytes suppresses 
Dexametasone/cAMP-induced induced activation of phosphoenolpyruvate carboxykinase (PEPCK) 
promoter causing inhibition of hepatic gluconeogenesis. 
Growing evidence suggest that increases in Id2 may have functional effects on metabolic 
genes (79). The bHLH-L/Z transcription factor SREBP is essential for adipocyte 
differentiation and the expression of genes controlling lipid metabolism (74), and Id2 has 
been shown to bind to and inhibit the activity of SREBP-1c (74). SREBP-1 stimulates the 
promoter of the cholesterol ester hydrolase (hormone-sensitive lipase; HSL), the enzyme 
responsible for cholesterol ester hydrolysis in macrophages (79). Furthermore, experiments 
in J774.2 cells shows that Id2 antagonizes the stimulatory effects of SREBP-1, and down-
regulates SREBP-1 mediated induction of HSL promoter activity, suggesting a role for Id2 
in glucose-mediated cholesterol ester deposition in macrophages (79, 81) (see below). 
1.5 Hyperglycaemia and cardiovascular disease 
Early events in atherosclerosis involve adhesion of circulating monocytes to the vascular 
endothelium, followed by transmigration of monocytes into the subendothelial space (82). 
CAT/Luc 
  B   Dex/cAMP Dx/cAMP/Ins Dx/cAMP/Id2 
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In response to the secretion of macrophage-colony stimulating factor (M-CSF) by activated 
smooth muscle cells and endothelial cells, monocytes differentiate into macrophages (83). 
Macrophages express scavenger receptors for modified lipoproteins, such as oxidized LDL, 
and ox-LDL accumulate large amount of cholesterol ester, resulting in the formation of 
lipid-laden foam cells (83, 84). Both the process of monocyte transmigration and 
macrophage CE accumulation is increased under hyperglycaemic conditions. The effect of 
hyperglycaemia is, at least in part, due to increased expression of vascular cell adhesion 
molecule-1(VCAM-1) and monocyte chemo attractant protein-1 (MCP-1) on endothelial 
cells, mediated by intracellular stress and activation of NF-κB (85, 86) (Figure 1.5) 
 
 
 
 
Fig.1.5 Role of macrophage inflammation of the 
artery. Adhesion of circulating monocytes to the 
vascular endothelium, and transmigration of 
monocytes into the subendothelial space, followed 
by differentiation into macrophages, and 
ultimately, to inflammation and tissue damage 
(Figure is adapted from Hansson GK, 2005 (87)).  
 
 
 
It is now well established that growth factors and cytokines can act to promote 
atherogenesis. However, little is currently known about how cholesterol ester metabolism in 
macrophages is affected by the conditions that characterize type-2 diabetes, insulin 
resistance, and obesity such as hyperglycaemia, hyperleptinemia and hyperinsulinemia. In 
murine J774.2 macrophages chronic exposure to hyperglycaemia increases the uptake of ox-
LDL by up-regulation of scavenger receptor CD36 with no net increase in cholesterol ester 
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accumulation (81). When these cells were exposed to hyperglycaemia in combination with 
insulin or leptin, the rate of cholesterol ester deposition increased significantly through up-
regulation of the activity of the main enzyme responsible for cholesterol ester synthesis, 
acyl-CoA:cholesterol O-acyltransferase, (ACAT) and down-regulation of HSL protein 
expression and activity (81).  
As previously explained, Id2 is likely to mediate down-regulation of HSL promoter activity 
(79). Interestingly, Id2 is also one of the genes found to be over expressed in muscle, fat and 
liver of ob/ob mice (79). These mice are a genetic model of obesity and severe insulin 
resistance (88).  Furthermore, preliminary data indicates that Id2 knock out mice are 
resistant to development of atherosclerosis suggesting that Id2 contributes significantly to 
the atherogenic process.  
1.6 Aim of study 
Previous work in J774.2 murine macrophages shows that Id2 is up-regulated by 
hyperglycaemia via the hexosamine signalling pathway, involving the rate-limiting enzyme, 
GFAT, and the enzyme responsible for O-linked glycosylation of proteins, OGT. When 
J774.2 cells are exposed to hyperglycaemia in combination with insulin or leptin, the rate of 
cholesterol ester deposition increase through up-regulation of ACAT and down-regulation of 
HSL. Overexpression of Id2 is able to suppress HSL promoter activity in J774.2 cells, 
suggesting a role of Id2 in glucose-mediated cholesterol ester deposition. The role of 
hyperglycaemia and hexosamine signalling pathway in human macrophages has not yet been 
studied, and specific aims of this study in primary human macrophages are to: 
· investigate high glucose/hexosamine-mediated regulation of Id2 and Id1 protein expression 
· study the effect of hyperglycaemia/hexosamine on subcellular distribution of Id2 
· study hyperglycaemia/hexosamine-induced O-GlcNAcylation of Id2 
· investigate high glucose/hexosamine-mediated regulation of GFAT protein expression 
· investigate high glucose/hexosamine-mediated regulation of OGT protein expression 
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· study the subcellular distribution of OGT and O-GlcNAcylated proteins in normoglycaemic 
versus hyperglycaemic cells  
· identify novel hexosamine-induced O-GlcNAcylated proteins  
 
Due to the observation that the fructose transporter Glut 5 is strongly up-regulated in human 
macrophages during differentiation, one specific aim is to:  
· investigate whether fructose induces the protein expression of Id1, Id2, GFAT and OGT 
and whether fructose affects the abundance of O-GlcNAcylated proteins in primary human 
macrophages 
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2. Methods 
2.1 Isolation of human monocytes 
Peripheral blood mononuclear cells (PBMC) can be isolated from whole blood using 
different density gradient centrifugation procedures. Anticoagulated whole blood is layered 
over the separation medium, and at the end of the centrifugation step, the following layers 
are visual (from top to bottom): Plasma/platelets, PBMC, separating medium and 
erythrocytes and granulocytes. The PBMC layer is then collected and washed to get rid of 
contaminants before cell type and cell viability can be confirmed. 
Materials: 
- Anticoagulated whole blood (Ullevål Hospital, Norway) 
- Lymphoprep (Fresnius Kabi Norge AS, Norway) 
- PBS (free of LPS, without Ca2+ and Mg2+) (Gibco; Invitrogen, Norway; cat.no: 10010-015) 
- RPMI 1640 medium/ GlutaMAXTM-1 (Gibco; Invitrogen, Norway; cat.no: 61870)  
- Human AB serum (Bio WhittakerTM; cat.no: 14-490E)  
- M-CSF (PEPROTECH EC, UK; cat.no: 300-25)  
- Penicillin/ Streptomycin (Gibco; Invitrogen, Norway; cat.no: 15140-122) 
- 10 cm cell culture plates (NUNCTM, Denmark; cat.no: 15140-122) 
- Centrifuge with cooler (Jouan CR412, USA) 
- Cell counter (Beckman coulterTM Z2 coulterR Particle count and size Analyzer, Nerliens 
Meszansky AS, Noway) 
- CO2 Air-Jackeded Incubator DH Autoflow (NUAIRETM, UK)  
Procedure: 
Buffy coats were obtained from healthy donors at the Ullevål hospital blood bank. The 
contents of the buffy coat were transferred to 5 falcon tubes (50 ml), and 35 ml PBS (free of 
LPS with no calcium or magnesium) was added to each tube. The samples were mixed by 
pipetting, and then 10 ml lymphoprep was carefully added to the bottom of each tube. The 
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samples were then spinned at 500 x g for 30 min at room temperature, with no brake. The 
cells recovered from the interface were transferred into 2 new falcon tubes.  Cells were 
washed two times by adding PBS up to 50 ml, spinning the tubes at room temperature for 10 
min at 500 x g and discarding the supernatant. Cell pellets were then resuspended in PBS 
and transferred to one tube. PBS was added to 50 ml, and the tube was spinned for 5 min at 
300 x g at room temperature. Cell pellet was then resuspended in 10 ml RPMI 1640 
medium/GlutaMAXTM-1 and the cells were counted using Beckman CoulterTM Particle count 
and size Analyzer. RPMI 1640 medium/GlutaMAXTM-1 was added to achieve the 
concentration of 2.5-3 mill. cells/ml. 10 % human AB serum was added, and the cell solution 
were transferred to 10 cm cell culture plates, 10 ml to each dish. The cells were allowed to 
adhere to plastic for 1 hour at 37˚C in a humidified 5 % CO2 atmosphere before the medium 
was removed, and the cells were washed extensively 3 x in PBS in order to remove 
contaminant cells. 10 ml RPMI 1640 medium containing 5 % human AB serum, 25 ng/ml 
macrophage-colony stimulating factor (M-CSF) and 1 % penicillin/ streptomycin were 
added to the remaining adherent monocytes, and the monocytes were incubated for 7 days at 
37˚C in humidified 5 % CO2 atmosphere to differentiate to macrophages. 
2.2 Stimulation of cells 
Materials: 
- PBS (without Ca2+ and Mg2+) (Gibco; Invitrogen, Norway; cat.no: 10010-015) 
- D-glucose medium: (RPMI 1640 (without glucose) (Gibco; Invitrogen, Norway; cat.no: 
11879-020), D-Glucose (Sigma-Aldrich Co, USA; cat.no: G 6152))    
- D-(+)-glucosamine hydrochloride (Sigma-aldrich Co, USA; cat.no: G 4875) 
- D-fructose (Sigma-Aldrich Co, USA; cat.no: F 2543)  
-O-(-2-acetamido-2-deoxy-D-glucopyranosylidine amino N-phenylcarbamate)           
(PUGNAc) (Toronto Chemical Inc)    
- Insulin (from bovine pancreas) (Sigma-Aldrich Co, USA; cat.no: I-6634)   
- Leptin (from mouse) (AbD Serotec, UK; cat.no: PMP 25) 
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Procedure: 
After 7 days in culture, the macrophages adhered to the plates were washed 2 x with 10 ml 
PBS. The cells were then incubated over night at 37˚C in humidified 5 % CO2 atmosphere in 
RPMI 1640 medium (with L-glutamine, without glucose) containing 1 % human AB serum 
and 0.5 mM or 5 mM D-glucose. The next day the cells were stimulated with various 
glucose concentrations or in the absence or presence of insulin and/or leptin, glucosamine, 
PUGNAc or fructose in RPMI 1640 medium (with L-glutamine, without glucose) containing 
1 % human AB serum and 0.5 mM, 5 mM or 20 mM D-glucose. Stimulation with 
glucosamine, PUGNAc and fructose were only performed in normoglycaemic conditions (5 
mM glucose).  
2.3 Cell lysate preparation 
Materials: 
- PBS (without Ca2+ and Mg2+) (Gibco; Invitrogen, Norway, cat.no: 10010-015) 
- Cell scrapers (3008) (CostarR, USA; cat.no: SPD 273384) 
- Centrifuge with cooler (Centrifuge 5415R, Eppendorf GmbH, Germany)  
- Heating block (Ori-Block 08-1, Techne) 
- 1 x Loading buffer:  
· Glycerol (Sigma-Aldrich Co, USA; cat.no: G 5516) 
· SDS (Sigma-Aldrich Co, USA; cat.no: L 4509) 
· DTT (Fermentas, Sweden; cat. no: R 0861) 
 · Bromophenol blue (Sigma-Aldrich Co, USA; cat.no: B 0126) 
· Tris/HCl (Sigma-Aldrich Co, USA; cat.no: T 1503)   
- 1 x RIPA-buffer:  
· (Tris/HCl (Sigma-Aldrich Co, USA; cat.no: T 1503)   
· NaCl (Fluka Chemicals GmbH, Germany; cat.no: 71381) 
· Sodium dodecyl sulfate (SDS) (Sigma-Aldrich Co, USA; cat.no: L 4509)  
· NP-40 (BioVision, USA; cat.no: 2111-100) 
· Na- Deoxycholate (Sigma-Aldrich Co, USA; cat.no: D 6750) 
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· EDTA (Sigma-Aldrich Co, USA; cat.no: E 5134) 
· Tx-100 (Sigma-Aldrich Co, USA; cat.no: X 100) 
· ALLN (CalbiochemR, USA; cat.no: 208719) 
· AEBSF (CalbiochemR; USA: cat.no: 101500) 
· Mix of protease inhibitors (Roche Diagnostics, Germany; cat.no: 13181300) 
· DTT (Fermentas, Sweden; cat.no: R 0861) 
· NaF (Sigma-Aldrich Co, USA; cat.no: S 6776)  
· Na4PO2O7 (Sigma-Aldrich Co, USA; cat.no: S 9515) 
· N3VO4 (Sigma-Aldrich Co, USA; cat.no: S 6508) 
Procedure: 
The plates were placed on ice, and the cell monolayers were washed 3 x in 10 ml ice-cold 
PBS carefully added to one side of the plate and removed by suction. After removal of PBS, 
200 μl RIPA buffer were added to the cell monolayer in order to lyse the cells. The lysates 
were then scraped of the plate and transferred to ice-cold eppendorf tubes. The tubes were 
incubated on ice for 30 min and insoluble fraction was removed from the lysates by 
centrifugation at 14 000 rpm for 10 min at 4˚C. The supernatants were then transferred to 
new, ice-cold eppendorf tubes and 20 μl was removed for protein concentration 
measurements. 50 μl 5 x Loading Buffer was added to 200 μl lysate and the samples were 
boiled for 5 min. 
2.4 Measurement of protein concentration 
The Bio-Rad Protein Assay, based on the method of Bradford, is an accurate procedure for 
determining concentration of solubilised protein. Assay Dye Reagent Concentrate is added 
to a protein sample and differential colour change of the dye occurres in response to various 
concentration of the protein  
Materials: 
- Albumine from bovine serum (BSA) (Sigma-Aldrich Co, USA; cat.no: A 9418) 
- RIPA buffer (as described) 
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- Bio-Rad Protein Assay Dye Reagent (Bio-RadTM, USA; cat.no: 500-0006) 
- Cyvettes (Chemi-Technik as, Norway) 
- Spectrophotometer (Ultrospec 3000, UV/visible spectrophotometer; Pharmacia Biotech) 
Preparation of a standard curve: 
A standard curve using different volumes of 1μg/μl BSA was prepared in order to provide a 
relative measurement of the protein concentrations. MilliQ H2O, BSA (1μg/μl) and RIPA 
buffer were transferred to eppendorf tubes as follows: 
Μg BSA (1μg/μl) 
(μl) 
Buffer dH20 (μl) 
1 1.0 4.0 795 
2 2.0 4.0 790 
4 4.0 4.0 790 
6 6.0 4.0 790 
8 8.0 4.0 790 
10  10.0 4.0 785 
Blank 0.0 4.0 795 
 
200 μl Bio-Rad Protein Assay Dye Reagent was then added to each tube, and the tubes were 
mixed by vortexing. The samples were incubated for 5 min at room temperature and then 
transferred to cyvettes. The cyvettes were placed in the spectrophotometer, and a standard 
curve was then detected from the different volumes of BSA. 
Protein measurements of lysates: 
2 parallels of each lysate were prepared in eppendorf tubes by adding 795 ml milliQ H2O, 2 
μl RIPA buffer and 2 μl of the lysates. 200 μl Bio-Rad Protein Assay Dye Reagent was 
added to each tube, and the tubes were mixed by vortexing. The contents of each tube were 
then added to cyvettes and the cyvettes were placed in the spectrophotometer. Measurements 
at 595 nm were performed and the relative protein concentrations of each lysate compared to 
the standard curve were then decided. 
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2.5 SDS polyacrylamid gel electrophoresis 
In order to visualize and separate protein, sodium dodecyl sulfate polyacryulamide gel 
electrophoresis (SDS-PAGE) was performed. SDS is an anionic detergent and a polypeptide 
chain binds amounts of SDS in proportions to its relative molecular mass. The negative 
charges on SDS destroy most of the complex structure of proteins, and are strongly attracted 
to an anode in an electric field. 
Materials: 
- CriterionTMPrecast gel (7.5 %) (Bio-RadTM, USA; cat.no: 345-005) 
- CriterionTMPrecast gel (10 %) (Bio-RadTM, USA; cat.no: 345-009) 
- CriterionTMPrecast gel (4-15 %) (Bio-RadTM, USA; cat.no: 345-0027) 
- CriterionTMPrecast gel (15 %) (Bio-RadTM, USA; cat.no: 345-0019) 
- 1 x Running buffer  
· Tris/ HCl (Sigma-Aldrich Co, USA; cat.no: T 1503) 
· Glycine (Sigma-Aldrich Co, USA; cat.no: G 7126)  
· SDS (Sigma-Aldrich Co, USA; cat.no: L 4509) 
- Precision Plus Protein Standards (All blue) (Bio-RadTM, USA; cat.no: 161-0373)   
- Precision Plus Protein Standards (Dual colour) (Bio-RadTM, USA; cat.no: 161-0374) 
- BIORAD Criterion System (Bio-RadTM, USA) 
Procedure: 
CriterionTMPrecast gel was transferred to the BIORAD Criterion System and the chamber 
was filled with 1 x Running buffer. The same amount of protein (~ 35 μg) as well as 
Precision Plus Protein Standards (All blue and Dual colour) was carefully loaded to each 
well. The lid was placed on the chamber and electrophoresis was performed under constant 
voltage of 150 V for about 90 min. 
2.6 Wet transfer and western blot 
Samples were transferred from polyacrylamide gels to Immobilon-Polyvinylidene fluoride 
(PVDF) blotting membrane using BIORAD Criterion blotter system. 
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Materials: 
- Immobilon-Polyvinylidene fluoride (PVDF) blotting membrane (Millipore, Norway; 
cat.no: IPVH00010) 
- GFAT (Nerlich, 1998 (39)) 
- OGT/AL28 (Hart, 2003 (45)) 
- Id1 (c-20) rabbit polyclonal IgG antibody (Santa Cruz Biotechnology, Santa Cruz; cat.no: 
Sc-488) 
- Id2 (c-20) rabbit polyclonal IgG antibody (Santa Cruz Biotechnology, Santa Cruz; cat.no: 
Sc-489) 
- CTD 110.6 monoclonal antibody (Covance, UK, cat.no: MMS-248R) 
- RL-2 monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz; cat.no: Sc-59624) 
- Goat Anti-Rabbit IgG secondary antibody (Jackson immuno research, USA; cat.no: 111-
035-144) 
- Goat Anti-Mouse IgM Secondary antibody (Sigma-Aldrich Co, USA; cat.no: A 8786) 
- 10 x Towbin buffer:  
· Tris/HCl (Sigma-Aldrich Co, USA; cat.no: T 1503) 
· Glycine (Sigma-Aldrich Co, USA; cat.no: G 7126) 
· Methanol (BDH-Prolab, UK; cat.no: UN-1230) 
- 1 x TBS-T: 
· Tris/HCl (Sigma-Aldrich Co, USA; cat.no: T 1503) 
· NaCl (Fluka, Germany; cat.no: 71381) 
· Tween 20 (Sigma-Aldrich Co, USA; cat.no: P 9416) 
- 3 % Albumine from bovine serum (BSA) (Sigma-Aldrich Co, USA; cat.no: A 9418) in 
TBS-T 
- Fibre pads (Bio-RadTM, USA) 
- Filter papers (Bio-RadTM, USA) 
- Methanol (BDH-Prolab, UK; cat.no: UN-1230) 
- Ponceu (0.1 %)(v/v) in 5 % acetic acid (v/v)(Sigma-Aldrich Co, USA; cat.no: P 7170)  
- Supersignal West Pico Chemiluminescent substrate (PIERCE, USA; cat.no: 34080) 
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- ECL Supersignal West Dura extended Duration Substrate (PIERCE, USA; cat.no: 34076) 
- Rocking platform (Platform STR8, Stuart Scientific, UK) 
- Hypercassette (Amersham Biosciences, UK)  
- Hyperfilm TM MP (Amersham Biosciences, UK) 
- Developer (Curix 60, AGFA GEVAERT N.V., Germany) 
Procedure: 
PVDF membrane and filter papers were cut to cover the gel. In order to rehydrate the 
membrane, it was soaked in methanol, rinsed in distilled water and transferred to 10 x 
Towbin buffer. Fibre pads and filter papers were then immersed in 10 x Towbin buffer, and 
filter pads, filter papers, gel and PVDF membrane were transferred to the cassette and placed 
in the blotting tank. An ice cooling unit was added to the tank which was filled with 10 x 
Towbin buffer and set at 100 V for 1 hour. After 1 hour the membrane was dyed with 
Ponceu solution to compare the protein concentration in the wells. The membrane was then 
washed in distilled water to remove the Ponceu solution, and in order to saturate the binding 
sites, the membrane was removed to 3 % Albumine from bovine serum (BSA) in TBS-T and 
incubated on a rocking platform for 1 hour at room temperature. 
Next, primary antibody was diluted in BSA in TBS-T at desired concentration, and the 
membrane was transferred to the antibody solution and incubated on a rocking platform over 
night at 4ºC. The next morning the membrane was washed 3 x 5 minutes with TBS-T, and 
then incubated for 45 minutes in a suitable secondary antibody conjugated to horseradish 
peroxidise (HRP) diluted in TBS-T at the concentration 1:10 000. The membrane was 
washed 3 x 5 minutes with TBS-T and rinsed in distilled water, ECL solution was prepared 
and the membrane was incubated with this solution for 5 minutes. The membrane was then 
transferred to a cassette and developed using HyperfilmTM MP and Curix 60 AGFA 
developer. 
 
 
 34 
2.7 Immunoprecipitation (IP) 
Materials: 
- RIPA buffer (as described) 
- Id2 (c-20) rabbit polyclonal IgG antibody (Santa Cruz Biotechnology, Santa Cruz; cat.no: 
Sc-489) 
- CTD110.6 monoclonal antibody (Covance, UK; cat.no: MMS-248R) 
- Protein A/G PLUS-Agarose (Santa Cruz Biotechnology, Santa Cruz; cat.no: Sc-2003) 
Procedure: 
The plates were placed on ice, and the cell monolayers were washed 3 x in 10 ml ice-cold 
PBS carefully added to one side of the plate, and removed by suction. After removal of PBS, 
RIPA buffer was added in various volumes, depending on the desired final concentration of 
the IP-solutions, to the cell monolayer in order to lyse the cells. The lysates were then 
scraped of the plate and transferred to ice-cold eppendorf tubes, two plates were mixed in 
each tube. The tubes were then incubated on ice for 30 min, and insoluble fraction was 
removed from lysate by centrifugation at 14 000 rpm for 10 min at 4˚C. Supernatants were 
transferred to new, ice-cold eppendorf tubes and 20 μl was removed for protein 
concentration measurements. Subsequently, the samples, in the presence of 30 μl Protein G 
Agarose beads and in the absence or presence of Id2 antibody (1:100 dilution) or CTD110.6 
antibody (1:2000), were incubated at 4ºC over night (Id2) or for 3 hours (CTD110.6). Then 
the beads were washed 3 x with PBS and resuspended in 30 μl 2 x Loading Dye and boiled 
for 5 minutes. 
2.8 Nuclear extract (NE) preparation 
Materials: 
- Hanks’ Balanced Salt Solution (HBSS) (PAA Laboratories GmbH, Austria; cat.no: H15-
009) 
- 0.1 % fatty free BSA (Sigma-Aldrich Co, USA; cat.no: A 6003) in HBSS  
- PBS (without Ca2+ and Mg2+) (Gibco; Invitrogen, Norway; cat.no: 10010-015) 
- TBS-T (as described) 
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- Hypotonic buffer  
· Tris/HCl (Sigma-Aldrich Co, USA; cat.no: T 1503)  
· NaCl (Fluka Chemicals GmbH, Germany; cat.no: 71381) 
· MgCl2 (Sigma-Aldrich Co, USA; cat.no: M 4880) 
· ALLN (CalbiochemR, USA; cat.no: 208719) 
· AEBSF (CalbiochemR, USA; cat.no: 101500) 
· Mix of protease inhibitors (Roche Diagnostics, Germany; cat.no: 13181300) 
- Dent & Latchman buffer  
· Hepes (Sigma-Aldrich Co, USA; cat.no: H 4034) 
· Glycerol (Sigma-Aldrich Co, USA; cat.no: G 5516) 
· MgCl2 (Sigma-Aldrich Co, USA; cat.no: M 4880) 
· EDTA (Sigma-Aldrich Co, USA; cat.no: E 5134) 
· ALLN (CalbiochemR, USA; cat.no: 208719) 
· AEBSF (CalbiochemR, USA; cat.no: 101500) 
· Mix of protease inhibitors (Roche Diagnostics, Germany; cat.no: 13181300) 
· DTT (Fermentas, Sweden; cat.no: R 0861) 
Procedure: 
The medium was removed from each dish (10 cm) and 5 ml HBSS/0.1 % BSA (fatty acid 
free) was added. The cells were then scraped and two and two parallels were transferred to 
15 ml falcon tubes and mixed well by quick vortexing. The cells were then spinned at 320 
RCF for 5 min at 4ºC. The supernatant was removed, 1 ml PBS was added to each tube and 
the pellet was dissolved by flicking on the tube. The solutions were transferred to cold 1.5 
ml eppendorf tubes and spinned at 320 RCF for 5 min at 4ºC. The supernatant was carefully 
removed and the pellet was resuspended in 450 μl of hypotonic buffer by vortexing. 50 μl 5 
% NP-40 was added and immediately, the tubes were flicked on, and the cells were spinned 
at 120 RCF for 5 min at 4ºC. Post nuclear supernatant (PS) was transferred to new, cold 
eppendorf tubes and stored at -70ºC. Nuclear pellet was resuspended in 1 ml hypotonic 
buffer, (10 μl was removed in order to study the whole nuclei in microscope) and the tubes 
were spinned at 120 RCF for 5 min at 4ºC. The supernatant was removed and 100 μl Dent 
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and Latchman buffer as well as 5 M NaCl to final concentration of 400 mM was added. The 
samples were vortexed for 3 seconds and incubated on a roller for 30 min at 4ºC. The tubes 
were then spinned at 14000 RPM for 30 min at 4ºC, and supernatants were transferred to 
new, cold eppendorf tubes and stored at -70ºC (20 μl of the samples was removed for 
concentration measurements). 
2.9 Immunoflourescence (IF) 
Materials: 
- PBS (without Ca2+ and Mg2+) (Gibco; Invitrogen, Norway; cat.no: 10010-015) 
- PBS-T 
 · PBS (without Ca2+ and Mg2+) (Gibco; Invitrogen, Norway; cat.no: 10010-015) 
 · Tween 20 (Sigma-Aldrich Co, USA; cat.no: P 9416) 
- Saponin (Fluka Chemicals GmbH, Germany; cat.no: 84510) 
- Fixatives (formaldehyde) (Sigma-Aldrich Co, USA; cat.no: F 8775) 
- 0.2 % saponin in PBS  
- 0.2 % saponin in PBS-T  
- PBST-BSA- 0.2 % saponin   
- Id2 (c-20) rabbit polyclonal IgG antibody (Santa Cruz Biotechnology, Santa Cruz; cat.no: 
Sc-489) 
- RL2 monoclonal antibody (Snow, 1987 (97)) 
- OGT/AL28 (Hart, 2003 (45))  
- Alexa 488: FITC/Green Rabbit secondary antibody (Molecular Probes, USA; cat.no: A 
11008) 
- Alexa 546: Red Mouse secondary antibody (Molecular Probes, USA; cat.no: A 11003) 
- DAPI  (Molecular Probes, USA)  
- Dakocytomation fluorescent mounting medium (DAKO) (Dakocytomation, Denmark; 
cat.no: S 3023)  
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Procedure: 
The cells were cultivated on cover slips in 12 well plates, and after 7 days, media was 
removed and the cells were washed 3 times in PBS (with no calcium or magnesium). Excess 
fluid was removed, 100 μl fixatives were added and the cells were incubated for 15 min at 
room temperature. The lid was placed on to avoid evaporation. Fixatives were removed and 
the cells were rinsed and washed 2 x 5 min in PBS before permeabilization of the cells in 
100 μl 0.2 % saponin in PBS for 15 min at room temperature, with lid placed on. The cells 
were washed 2 x 5 min in PBST containing 0.2 % saponin, followed by incubation for 15 
min in 100 μl blocking buffer containing PBST with 2 % BSA including 0.2 % saponin. 
Next, primary antibody solutions were made up at desired concentration (usually 1:100) in 
PBST-BSA-0.2 % saponin.  Blocking solution was removed and 40 μl antibody solutions 
were added onto each sample and incubated for 60 min at room temperature before the cells 
were washed 3 x 5 min in PBST-BSA-0.2 % saponin followed by incubation in secondary 
rabbit or mouse Alexa antibody solution at the concentration 1:500 in PBST-BSA-0.2 % 
saponin for 30 min at room temperature. The lid was placed on and the plate covered by a 
polystyrene box to avoid fading of fluorescent dyes. The cells were then washed 2 x 5 min 
with PBST and incubated with DAPI diluted 1:50 000 in PBST in order to stain the nucleus. 
The slides were mounted with 10 μl antifade mounting media (DAKO) and dried in the dark 
over night at room temperature. 
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3. Results 
3.1 Effects of hyperglycaemia on Id1 and Id2 protein levels 
Previous studies have shown that Id1 protein is regulated by glucose in pancreatic  β-cells 
(77), and Id2 protein in J774.2 macrophages has also been shown to be glucose regulated 
(79). Glucose-mediated regulation of Id1 and Id2 in primary human macrophages has not yet 
been studied. Primary human macrophages were treated with 0.5 mM, 5 mM or 20 mM D-
glucose for 30 minutes, 60 minutes, 24 hours or 48 hours. Figure 3.1 shows that the relative 
protein levels of Id1 and Id2 are not affected by hyperglycaemia in primary human 
macrophages. 
 
Fig.3.1 Id1 and Id2 protein expression are not affected by hyperglycaemia in primary human 
macrophages. Primary human macrophages were treated with 0.5, 5 or 20 mM D-glucose for the 
indicated times. Cells were lysed in RIPA buffer and samples were separated on SDS-PAGE. Id1 and 
Id2 protein level were determined by Western blotting.  
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3.2 Effects of hyperglycaemia on Id1 and Id2 protein level in the presence of insulin 
and/or leptin 
In contrast to primary human macrophages, Id2 protein levels are up-regulated by 
hyperglycaemia in the murine J774.2 macrophage cell line. Human macrophages express 
insulin receptors and the glucose transporter Glut1. It is currently not known whether insulin 
via PI3-kinase signalling promote glucose uptake in human macrophages. For this reason, 
we wanted to investigate whether treatment with insulin or leptin (strong activator of PI3-
kinase in macrophages) would affect Id2 and Id1 protein expression in hyperglycaemia 
treated cells. Furthermore, Id mRNA expression has been shown to increase in response to 
serum or growth factors, including insulin (77). Primary human macrophages were treated 
with 5 mM or 20 mM D-glucose in the absence or presence of insulin and/or leptin for 24 
hours. Figure 3.2 shows that Id1 is slightly up-regulated by insulin in normoglycaemic 
conditions, while in hyperglycaemic conditions, insulin and leptin together up-regulate Id1. 
Figure 3.2 also shows that Id2 is strongly up-regulated by insulin at both normoglycaemic 
and hyperglycaemic conditions suggesting that high glucose does not affect Id2 protein level 
in primary human macrophages. Furthermore, under normoglycaemic conditions, leptin up- 
regulates Id2 protein, in agreement with previously performed micro array experiments in 
J774.2 cells (data not shown). This suggests that leptin-mediated up-regulation of Id2 
protein expression in primary human macrophages occurs at the transcriptional level. All 
together, these results suggest that Id1 mRNA is up-regulated by insulin, and that both 
insulin and leptin up-regulate Id2 mRNA in macrophages with no further effect of high 
glucose. 
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Fig.3.2 Insulin treatment increases Id1 and Id2 protein level in primary human macrophages. 
Primary human macrophages were incubated in 0.5, 5 or 20 mM D-glucose for 24 hours in the 
absence or presence of insulin and/or leptin. Cells were lysed in RIPA buffer and samples were 
separated on SDS-PAGE. Id1 and Id2 protein level were determined by Western blotting.  
Membranes were stained using Ponceu. Representative of two individual experiments performed in 
duplicate. 
3.3 Effects of glucosamine on Id1 and Id2 protein levels 
Glucosamine-6-phosphate is formed by the conversion of fructose-6-phosphate by the rate 
limiting enzyme GFAT, but this molecule can also be produced by the phosphorylation of 
glucosamine. Glucosamine is transported into the cells via the Glut family of facilitative 
glucose transporters, and is phosphorylated to glucosamine-6-phosphate. The molecule 
enters the hexosamine signalling pathway downstream of GFAT, and is able to mimic the 
effect of glucose acting via this particular pathway (79). To study the effect of glucosamine 
on the protein levels of Id1 and Id2, primary human macrophages, were treated with 5 mM 
D-glucose in the absence or presence of 2 mM D-glucosamine or the inhibitor of OGA, 
PUGNAc, for 4 hours or in the absence or presence of fructose for 4 hours. Figure 3.3 shows 
that both glucosamine and PUGNAc increases the protein level of both Id1 and Id2 after 4 
hours, but that the up-regulation of Id2 are stronger than of Id1.  
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Fig.3.3 Glucosamine and PUGNAc treatment increases level of Id1 and Id2 protein in Primary 
human macrophages. Primary human macrophages were incubated in 5mM D-glucose in the 
absence or presence of glucosamine (2mM), fructose (1mM) or PUGNAc. Cells were lysed in RIPA 
buffer, and samples were separated on SDS-PAGE. Id1 and Id2 protein level were determined by 
Western blotting. Membranes were stained using Ponceu. Representative of two individual 
experiments performed in duplicate. 
3.4 Effects of fructose on Id1 and Id2 protein levels 
During the past several years, consumption of fructose has increased considerably (1). 
Fructose is absorbed in the small intestine and mostly transported via the portal vein to the 
liver where it is metabolized by fructokinase to fructose-1-phosphate (89). Fructokinase is 
not present in extra-hepatic organs, but as serum concentration of fructose increases, fructose 
is converted to fructose-6-phosphate by hexokinase in extra-hepatic organs (1, 2).  The 
fructose transporter, Glut 5, is strongly up-regulated in macrophages during differentiation, 
suggesting that these cells become extremely sensitive to small increases in fructose levels 
(8). To study the effect of fructose on the protein levels of Id1 and Id2, primary human 
macrophages were treated with 5 mM D-glucose in the absence or presence of fructose for 4 
hours. Figure 3.4 shows that fructose strongly up-regulates the protein level of Id1after 4 
hours, and the Id2 protein level is also slightly increased. 
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Fig.3.4 Fructose treatment for 4 hours increases level of Id1 and Id2 in primary human 
macrophages. Primary human macrophages were incubated in 5 mM D-glucose in the absence or 
presence of fructose (1 mM). Cells were lysed in RIPA buffer and samples were separated by SDS-
PAGE. OGT and GFAT protein levels were determined by Western blotting. Representative of two 
experiments performed in duplicate.  
3.5 Identification of O-GlcNAcylated Id2 protein in primary human macrophages 
Experiments in J774.2 macrophages suggest that Id2 is target for O-GlcNAcylation (79). 
Here, we investigated whether Id2 is O-linked glycosylated in primary human macrophages. 
Cells, cultured under normoglycaemic conditions, were lysed in RIPA buffer and Id2 was 
immunoprecipitated over night and O-GlcNAcylated Id2 proteins were identified by SDS 
page and western blotting using CTD 110.6 monoclonal antibody against O-linked 
glycosylated (O-GlcNAc) proteins (Made specifically against C-terminal domain, a part of 
RNA polymerase II). In order to detect various O-GlcNAc-modified proteins, 
immunoprecipitation was performed using the CTD 110.6 monoclonal antibody for 3 hours, 
and protein levels of O-GlcNAcylated proteins, including Id2 (Figure 3.5A), were 
determined by SDS page and western blotting using CTD 110.6 monoclonal antibody and 
and Id2 polyclonal antibody. Figure 3.5B shows that Id2 was co-precipitated with the 
CTD110.6 antibody and also, spesific O-GlcNAc immunoreactive bands of approximately 
15, 30 and 50 kDa were detected in primary human macrophages. 
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Fig.3.5 Abundance of O-GlcNAylated Id2 protein. Primary human macrophages exposed to 
normoglycaemic conditions were lysed in RIPA buffer and Id2 was immunoprecipitated. SDS page 
and Western blotting was performed on whole cell lysates using Id2 polyclonal antibody and CTD 
100.6 monoclonal antibody against O-linked glycosylated (O-GlcNAc) proteins. Figure 5 A reveals 
specific Id2 and O-GlcNAc immunoreactive bands of 15 kDa and figure 5B reveals specific Id2 and 
O-GlcNAc immunoreactivebands at approximately 15, 30 and 50 kDa. 
3.6 Subcellular localization of Id2 
Appropriate subcellular localization is crucial for proper function of numerous proteins, and 
nucleo-cytoplasmic shuttling is a mechanism for regulation of the function of Id proteins 
(90). Nuclear export has been shown to play an inhibitory role in the suppressive activity of 
Id2 (90). A way to study the subcellular distribution of proteins is by immunoflourescense. 
Cells differentiated in 12-wells plates on cover slips were treated with 5 mM and 20 mM D-
glucose for 24 hours. Subsequently, the macrophages were treated with Id2 primary antibody 
diluted 1:50 for 1 hour before further treatment for 30 minutes with secondary Alexa 
antibody 488, diluted 1:500. In order to stain the nucleus, cells were incubated in DAPI, 
diluted 1:50 000, and the slides were mounted with DAKO antifade mounting media. Figure 
3.6 shows a stronger nuclear staining of Id2 in cells incubated in 5 mM D-glucose compared 
to 20 mM D-glucose, with slightly stronger cytoplasmic staining in cells treated with high 
glucose, suggesting active transport of Id2 to the cytoplasm after 24 hours in hyperglycaemic 
conditions. 
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Fig.3.6 Subcellular localization of Id2. Primary human macrophages differentiated in 12-wells 
plates on cover slips were treated with 5 mM and 20 mM D-glucose for 24 hours followed by 
treatment with Id2 primary antibody and secondary Alexa antibody 488. Nuclear staining was 
performed with DAPI.  
 
3.7 Effects of hyperglycaemia on GFAT and OGT protein expression 
In order to investigate the regulation of protein levels of GFAT and OGT by glucose, 
primary human macrophages were incubated in 0.5 mM, 5 mM or 20 mM glucose medium 
for 30 min, 60 min, 2 h, 24h or 48 h. Figure 3.7 shows that the relative protein levels of 
GFAT and OGT in primary human macrophages are not affected by hyperglycaemia.  
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Fig.3.7 GFAT and OGT protein level in primary human macrophages are not affected by 
hyperglycaemia. Primary human macrophages were treated with 0.5, 5 or 20 mM D-glucose for the 
indicated times. Cells were lysed in RIPA buffer and samples were separated by SDS-PAGE. OGT 
and GFAT protein levels were determined by Western blotting.  
 
3.8 Effects of hyperglycaemia in the presence of insulin and/or leptin on GFAT and 
OGT protein expression  
Conditions that characterize type-2 diabetes are hyperglycaemia, hyperleptinemia and 
hyperinsulinemia. In liver cells, insulin has been shown stimulate the synthesis of OGT (58), 
suggesting that insulin is able to affect gene transcription of OGT. As macrophage 
deposition of cholesterol ester has been shown to increase in response to high glucose in the 
presence of insulin or leptin (81), high glucose is suggested to induce cholesterol ester 
accumulation in macrophages by affecting insulin and/or leptin signalling. Moreover, insulin 
and leptin, possibly via PI3-kinase signalling might be able to modulate flux through the 
hexosamine signalling pathway by regulating GFAT expression and/or activity. Primary 
human macrophages were treated with 0.5, 5 or 20 mM D-glucose in the absence or presence 
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of insulin and/or leptin, and the results suggest that the relative protein levels of GFAT and 
OGT in primary human macrophages are not affected by hyperglycaemia in the presence of 
insulin and/or leptin (Figure 3.8). 
 
 
 
 
 
 
  
 
Fig.3.8 GFAT and OGT protein level in primary human macrophages are not affected by 
insulin and/or leptin. Primary human macrophages were treated with 0.5, 5 or 20 mM D-glucose for 
24 hours in the absence or presence of insulin and/or leptin. Cells were lysed in RIPA buffer and 
samples were separated on SDS-PAGE. OGT and GFAT protein level was determined by Western 
blotting. 
3.9 Effects of glucosamine on the regulation of GFAT and OGT protein expression 
In order to investigate the role of the hexosamine signalling pathway in the regulation of the 
protein levels of GFAT and OGT protein, primary human macrophages were incubated in 5 
mM D-glucose medium in the absence or presence of 0,2 mM or 2 mM D-glucosamine for 2 
or 6 hours. Western blots show that the relative protein levels of GFAT and OGT in primary 
human macrophages are not affected by glucosamine (Figure 3.9).  
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Fig.3.9 Glucosamine treatment does not affect OGT or GFAT protein level in primary human 
macrophages. Primary human macrophages were treated with 0, 5 or 20 mM D-glucose for 2 or 6 
hours in the absence or presence of glucosamine (0.2 or 2mM as indicated). Cells were lysed in RIPA 
buffer and samples were separated by SDS-PAGE. OGT and GFAT protein levels were determined 
by Western blotting.  
3.10 Effects of fructose on GFAT and OGT protein level 
Fructose-6-phosphate is substrate for GFAT in the hexosamine signalling pathway, and in 
order to investigate regulation of the protein levels of GFAT and OGT by fructose, primary 
human macrophages were incubated in 5 mM D-glucose medium in the absence or presence 
of 1 mM fructose. Figure 3.10 shows that the relative protein levels of GFAT and OGT in 
primary human macrophages are not affected by fructose at 4 hours.  
 
 
 
 
Fig.3.10 GFAT and OGT protein level in Primary human macrophages is not affected by short 
term stimulation by fructose. Primary human macrophages were treated with fructose (1mM) in 
5mM D-glucose for 4 hours. Cells were lysed in RIPA buffer and samples were separated by SDS-
PAGE. OGT and GFAT protein levels were determined by Western blotting.  
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3.11 The effect of hyperglycaemia on the subcellular localization of OGT 
OGT enzyme activity and targeting of O-GlcNAc cycling is suggested to be tightly regulated 
by protein interactions (52, 53, 65, 66,), tyrosine phosphorylation and autoglycosylation (56) 
This regulation is strongly influenced by environmental factors, and the concentration of 
UDP-GlcNAc, which increases in response to hyperglycaemia, has been shown to play a key 
role in regulating the enzymatic activity (35). The enzymatic activity may be due to 
subcellular localization of this enzyme, and in order to investigate whether the distribution 
of OGT is regulated by high glucose and/or glucosamine, nuclear extract preparation and 
immunflouresence were performed. Primary human macrophages were treated with 5 mM or 
20 mM D-glucose or 5 mM D-glucose in the presence of glucosamine (0.2 or 2 mM) or 
fructose (1mM) and the cells underwent nuclear extract preparation. The relative protein 
level of the nuclear extracts was determined by SDS page and western blotting. Figure 
3.11A shows that nuclear OGT protein levels are up-regulated in response to high glucose, 
glucosamine and fructose suggesting that high glucose and fructose is able to regulate the 
localization of OGT protein via the hexosamine signalling pathway. 
The immunoflourescense experiment also shows the distribution of OGT and O-
GlcNAcylated proteins in primary human macrophages. Cells differentiated in 12-wells 
plates on cover slips were treated with 5 mM and 20 mM D-glucose for 24 hours. 
Subsequently, the macrophages were treated with OGT polyclonal antibody or RL2 
monoclonal primary antibody detecting O-GlcNAcylated proteins diluted 1:100 for 1 hour 
before further treatment for 30 minutes with secondary Alexa 488 and 562 antibodies, 
diluted 1:500. In order to stain the nucleus, the cells were incubated in DAPI, diluted 1:50 
000, before the slides were mounted with DAKO antifade mounting media. According to the 
immunoflouresence experiment, treatment with 20 mM glucose for 24 hours seem to 
increase the level of OGT protein, and the protein seemed to be localized mainly in the 
plasma membrane (Figure 3.11B). This is in contrast to previous findings determined by 
SDS page and western blotting in the current study. 
O-GlcNAcylated proteins seem to be localized in the nucleus in both normoglycaemic and 
hyperglyaecemic treated macrophages. 
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Fig.3.11 Subcellular localization of OGT A. Primary human macrophages were treated with 5 or 20 
mM D-glucose or 5 mM D-glucose in the presence of glucosamine (0.2 or 2 mM) or fructose and the 
cells underwent nuclear extract preparation. The relative protein level of the nuclear extracts was 
determined by SDS page and western blotting. 
B. Primary human macrophages differentiated in 12-wells plates on cover slips were treated with 5 
mM or 20 mM D-glucose for 24 hours followed by treatment with OGT polyclonal antibody or RL2 
monoclonal primary antibody detecting O-GlcNAcylated proteins before treatment with secondary 
Alexa 488 and 562 antibodies. Nuclear staining was performed with DAPI. 
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3.12 Identification of novel hexosamine-induced O-GlcNAcylated proteins 
Fructose-6-phosphate is substrate for GFAT in the hexosamine signalling pathway, and the 
fructose transporter Glut 5 is strongly up-regulated in macrophages. This makes it very 
interesting to study whether fructose will increase flux through the hexosamine signalling 
pathway and increase the abundance of GlcNAcylated proteins in human macrophages. 
Primary human macrophages were treated with 5 mM D-glucose in the absence or presence 
of 2 mM D-glucosamine or 1 mM fructose for 4 hours. Relative protein levels were 
determined by SDS page and detected by western blotting using CTD 110.6 monoclonal 
antibody against O-linked glycosylated (O-GlcNAc) proteins (A). Competition with 10 mM 
N-acetylglucosamine (B) reveals specific O-GlcNAc immunoreactive bands of 
approximately 80 and 250 kDa in the macrophages stimulated with fructose and 
glucosamine (Figure 3.12). 
 
 
Fig.3.12 Fructose and glucosamine treatment induces O-linked glycosylation on proteins. 
Primary human macrophages were treated with fructose (1mM) or GlcN (2mM) in 5mM D-glucose 
for 4 hours. Cells were lysed in RIPA buffer and SDS page and Western blotting was performed on 
whole cell lysates using CTD 110.6 monoclonal antibody against O-linked glycosylated (O-GlcNAc) 
proteins (A). Competition with N-acetylglucosamine (B) reveals specific O-GlcNAc immunoreactive 
bands of approximately 80 and 250 kDa. 
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4. Discussion 
4.1 Summary of results 
In the present study we demonstrate that fructose and glucosamine induce Id1 and Id2 
protein expression as well as the abundance of O-GlcNAclated proteins in primary human 
macrophages. Moreover, in accordance with previous observations in the J774.2 murine 
macrophages cell line, Id2 was found to be a target for O-linked glycosylation also in 
primary human macrophages.  
Furthermore, we demonstrated nucleo-cytoplasmic shuttling of Id2 and OGT by high 
glucose, but in contrast to observations in J774.2 cells, hyperglycaemia has no effect on the 
protein levels of Id1 and Id2. Finally, hyperglycaemia did not regulate GFAT and OGT 
protein levels in primary human macrophages. 
These data suggest that hyperglycaemia is not able to increase flux through the hexosamine 
signalling pathway in resting human macrophages as compared to mouse macrophages.  
4.2 Id1 and Id2 protein levels are up-regulated via the hexosamine signalling 
pathway, and Id2 protein is O-GlcNAcylated in primary human macrophages 
Previous studies in J774.2 macrophages show that hyperglycaemia increases the protein 
level of Id2 via the hexosamine signalling pathway (79), and Id1 protein has been shown to 
be regulated by glucose in pancreatic beta cells (77). The present study in primary human 
macrophages shows that high glucose has no effect on the protein level of Id1 and Id2. 
However, both proteins were up-regulated by glucosamine and PUGNAc, suggesting that 
increased flux through the hexosamine signalling pathway and O-linked glycosylation is 
involved in the up-regulation of these proteins, also in human macrophages. 
Under hyperglycaemic conditions, all cells experience hyperglycemia, but not all cells are 
affected by it. This depends on the glucose transporter expressed and whether or not the cells 
increase the uptake of glucose in response to hyperglycaemic conditions. Very few studies 
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have addressed the effect of hyperglycaemia on human macrophages, and according to this 
particular study we suggest that these cells are less sensitive to high glucose levels than 
mouse macrophages. In J774.2 cells, Id2 protein is up-regulated by hyperglycaemia via the 
hexosamine signalling pathway. We were able to reproduce the up-regulation of Id2 protein 
via increased flux through the hexosamine signalling pathway in primary human 
macrophages. However, any effects of hyperglycaemia were not observed, suggesting that 
flux through the hexosamine signalling pathway, under hyperglycaemic conditions, is not 
increased in human macrophages compared to murine cells. Hyperglycaemic damage is 
thought to be mediated by four different pathways, and in one of these pathways, the polyol 
pathway, the enzyme aldose reductase catalyzes the reduction of glucose-6-phosphate to 
sorbitol using (NADPH) as cofactor (11, 12). The opposing results of the regulation of Id2 
protein level in the current study compared to experiments in J774.2 macrophages, may be 
explained by the fact that murine macrophages express lower levels of aldose reductase 
compared to the human cells causing increased flux of glucose through alternative metabolic 
pathways downstream of glucose-6-phophate, such as the hexoxamine signalling pathway 
using fructose-6-phosphate and glutamine as substrates. This difference in intracellular 
glucose utilization may result in increased flux through the hexosamine signalling pathway 
in J774.2 macrophages compared to primary human macrophages.   
Furthermore, superoxide production by phagocytes is associated with a rapid increase in 
metabolism known as the ‘respiratory burst’, characterized by increased hexose 
monophosphate shunt (HMPS) activity, which produces NADPH, the substrate required by 
NADPH oxidase for the production of superoxide (91).  This process demands increased 
sources of glucose for NADPH production, and this may cause decreased hexosamine 
signalling pathway flux in macrophages.  
Appropriate subcellular localization is crucial for the proper function of numerous proteins 
(90). Large proteins shuttle between the nucleus and cytoplasm through nuclear pore 
complexes by virtue of their intrinsic nuclear localization signals (NLSs) and nuclar export 
signals (NESs). In contrast, small proteins with molecular masses of less than 40 kDa can 
freely pass through the nuclear membrane (92, 93). Nucleo-cytoplasmic shuttling appears to 
be a mechanism for regulation of the function of Id proteins. Nuclear export has been shown 
to play an inhibitory role in the suppressive activity of Id2 protein (90). Id proteins have 
molecular masses ranging from 13-18 kDa, thus Id2 protein has been shown to enter the 
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nucleus by passive diffusion, and nuclear export and cytoplasmic localization are dependent 
a NES in the C-terminal region (90). This nucleo-cytoplasmic shuttling of Id proteins is 
subject to diverse types of regulation. The subcellular localization of many proteins is 
regulated by protein modifications such as phosphorylation, and in this particular study, Id2 
was shown to be a target for O-GlcNAcylation. Using the YinOYang O-linked glycosylation 
Prediction Server (94), we have found a potential O-GlcNAcylation site at position 108 in 
the Id2 gene (Figure 4.1) suggesting a role for O-GlcNAcylation in the regulation of nucleo-
cytoplasmic shuttling of Id2. In future experiments, the effect of hyperglycaemia on the rate 
of O-GlcNAcylated Id2 will be addressed as well as the role of O-GlcNAclated Id2 in 
macrophage foam cell formation. 
In the present study, increased abundance of Id2 protein is observed in the cytoplasm in cells 
incubated in 20 mM D-glucose compared to 5mM D-glucose at 24 hours. This may be due to 
activation of nuclear export and a potential cytoplasmic association of Id2 and E 
proteins/bHLH transcription factors in the cytoplasm under hyperglycemic conditions. This 
may inhibit the transport of these transcription factors into the nucleus when dimerized to 
Id2. In future experiments, effects of hyperglycaemia on the subcellular distribution of Id2 
will be investigated in a time-dependent manner, and the effect of glucosamine and fructose 
will also be elucidated. 
Fig.4.1 O-GlcNAcylation site in the Id2. A potential O-GlcNAcylation site at position 108 in the 
Id2 gene suggesting modulation of NES-2 and involvement of O-GlcNAcylation in the regulation of 
nucleo-cytoplasmic shuttling of Id proteins. 
In addition to hyperglycaemia, hyperleptinemia and hyperinsulinemia, type-2 diabetes, 
insulin resistance, and obesity are associated with inflammation and production of pro-
inflammatory cytokines such as IL-12 and tumor necrosis factor alfa (TNF-alfa), as well as 
activation of T-cells. In vivo, glucose ingestion has been shown to induce increases in the 
pro-inflammatory transcription factor, NF-κB, and increases in TNF-α mRNA (86). In the 
bHLH N C 
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pathogenic environment of diabetes, cytokines and T-cells are likely to promote effects of 
high glucose in macrophages as LPS-activated murine macrophages have been shown to 
increase the uptake of glucose via up-regulation of Glut1 (95). Future investigations will 
include studies of hyperglycaemia in activated, human macrophages.  
4.3 GFAT protein expression is not regulated by high glucose via the hexosamine 
signalling pathway in primary human macrophages 
The protein level of GFAT in primary human macrophages has previously not been studied, 
but previous experiments in skeletal muscle indicate up-regulation of GFAT protein level at 
high concentration of saturated fatty acids. Moreover, experiments in a breast cancer cell 
line showed that GFAT protein level was up-regulated by epidermal growth factor (EGF) 
and glucosamine, while high glucose (25 mM) blocked the transcriptional effect of EGF on 
the GFAT gene (38).  The results in this study in primary human macrophages, indicates that 
GFAT protein level is not regulated by high glucose, most likely because resting human 
macrophages do not experience glucose toxicity in response to high external glucose levels. 
Furthermore, the production of superoxide in macrophages may reduce the flux through the 
hexosamine signalling pathway and make this pathway less sensitive for increased glucose 
concentrations.  
4.4 Subcellular distribution of OGT, but not protein level, is regulated by high 
glucose via the hexosamine signalling patway in primary human macrophages 
In liver cells, insulin has been shown to stimulate the synthesis of OGT and to enhance 
cytosolic staining of OGT (58). In the present study, western blotting experiments showed 
that the protein level of OGT in primary human macrophages was not affected by high 
glucose via the hexosamine signalling pathway. In contrast, immunoflourescence 
experiments revealed that treatment with 20 mM glucose for 24 hours appeared to increase 
the level of OGT protein as determined by stronger OGT staining in hyperglycaemic cells. 
The antibody used for this studies, AL28, obtained from Gerald Harts lab, has not been 
affinity-purified, and it has to our knowledge, not been used in immunoflourescence studies 
before. In future experiments, several different OGT antibodies will be tested.  
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OGT is subject for autoglycosylation and tyrosine phosphorylation, modulating enzyme 
activity, substrate recognition and localization (56). The concentration of UDP-GlcNAc, 
which increases in response to hyperglycaemia, has been shown to play a key role in 
regulating the enzyme activity (35). Western blotting experiments on nuclear extracts 
performed in this study indicates that nuclear expression of OGT protein is increased in high 
glucose treated primary human macrophages suggesting hyperglycaemia-mediated nuclear 
translocation of OGT in these cells. 
According to immunoflourescence experiments, using RL2 monoclonal antibody, O-
GlcNAcylated proteins in human macrophages seem to be localized in the nucleus in the 
cells treated with 5 mM and 20 mM D-glucose for 24 hours. This is in agreement with 
experiments that showed that staining of 4-cell embryos with RL2 reveals heavy nuclear 
staining (96). The abundance of O-GlcNAcylated proteins was expected to increase in 
response to hyperglycaemia, but this was not seen in this specific experiment. The antibody 
used, RL2, was made specifically against the epitope of nuclear pore (NP62) protein (97), 
and in future immunoflourescence experiments we will also use the CTD110.6 antibody as 
Alexa IgM secondary antibodies are now commercially available. 
4.5 Fructose up-regulates Id1 and Id2 protein level in primary human macrophages 
Consumption of fructose, primarily from fructose containing beverages, has increased 
considerably during the past several years (1). The main pathway for fructose metabolism is 
in the liver, due to the presence of the enzyme fructokinase (1). As serum concentration of 
fructose increases, due to the inability of the liver to metabolize the load completely, 
fructose is converted to fructose-6-phosphate by hexokinase in extra-hepatic organs (1, 2). 
The fructose transporter, Glut 5, is strongly up-regulated in macrophages during 
differentiation (Figure 4.2), and macrophages might become extremely sensitive for small 
increases in circulating fructose levels (8). In this particular study, fructose appears to up-
regulate the protein levels of Id1 and Id2 and we suggest that fructose enters the hexosamine 
signalling pathway in human macrophages in response to small increases in circulating 
serum fructose concentrations.  
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Fig. 4.2  Glut 5 in human macrophages is strongly  
up-regulated during differentiation Immunoblots of 
GLUT-1, -3, and -5 expressed in human cultured 
monocyte-derived macrophages over a 14-day 
differentiation period. A sample of membranes prepared 
from human brain (HB; right lane) was also blotted as an 
internal control. Mr, relative molecular weight. (Figure is 
adapted from Malide D et al.,1998 (8)) 
4.6 Identification of novel hexosamine-induced O-GlcNAcylated proteins 
According to the present study, fructose increases the abundance of O-GlcNAcylated 
proteins, suggesting that fructose increase flux through the hexosamine signalling pathway. 
These observations are supported by the involvement of the hexosamine signalling pathway 
in the desensitizing of the glucose transport system (32), and the ability of both glucosamine 
and fructose to induce insulin resistance, according to previous studies (98, 99, 100, 101). In 
one study, supplementing the diet of healthy males with 3 g fructose per kg of body weight 
per day, which increased total caloric intake by 25 percent, resulted in insulin resistance in 
only six days (98).  
Like the increased consumption of fructose during the past several years, glucosamine 
supplementation has increased considerably. This is primarily due to the belief that 
glucosamine is efficacious in improving symptoms and joint space narrowing of 
osteoarthritis of the knee (102, 103, 104, 105). However, one recent intervention trial did not 
show any significant benefits (106), but as glucosamine is available and relatively 
inexpensive, it is subject for widespread consumption. As glucosamine is classified as a 
nutritional supplement, it is subject to minimal regulation, and its effects on other chronic 
diseases as well as metabolic outcomes have not been well studied (107). As earlier 
mentioned, glucosamine consumption can result in insulin resistance, and another area of 
concern is its potential effect on lipid metabolism. In LDL receptor deficient male mice 
glucosamine consumption exacerbated hyperlipidemia (107). As mention earlier, superoxide 
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production by phagocytes depends on increased HMPS activity, and may cause decreases in 
the entering of glucose into the hexosamine signalling pathway in macrophages. Both 
fructose and glucosamine enter this pathway down-stream for glucose-6-phosphate, and are 
likely to be important sources for O-GlcNAcylation of proteins in primary human 
macrophages and potential promoters of macrophage foam cell formation. 
4.7 Methodological considerations 
In vitro studies in primary human macrophages may be confounded by genetic and 
physiological differences of the blood donors and profoundly influence the parameters under 
investigation. However, during the differentiation process that lasts for 7 days, cells are 
experiencing the same culture conditions, and this is likely to minimize the differences 
between cell populations. In future studies, for simplification, we will perform initial 
experiments in the THP-1 human macrophage cell line. Relevant, reproducible observations 
will then be verified in primary human macrophages.  
4.8 Further investigations 
One aspect that has not been investigated in the present study, is whether glucose uptake in 
macrophages is affected by conditions that characterize type 2 diabetes, insulin resistance 
and obesity; hyperglycaemia, hyperinsulinemia and hyperleptinemia. In macrophages, the 
mechanism of glucose uptake appears to be facilitated diffusion (108). Glucose is 
transported via facilitative glucose transporters, and during differentiation to macrophages, 
Glut 1 increases progressively, Glut 3 decreases rapidly and Glut 5 (which main function is 
as a fructose transporter) is strongly up-regulated (8). Phagocytosis is associated with 
dramatic changes in the metabolism of phagocytes (109), and the increased glucose uptake 
appears to be linked to changes in the carrier mediated transport system (108). In order to 
investigate whether hyperglycaemia alone or in the presence of insulin or leptin as well as 
fructose and glucosamine at normoglycaemia, affects glucose uptake in macrophages, 
further experiments will include glucose uptake assays as well as analysis of protein levels 
of Glut 1, 3 and 5. 
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5. Conclusion 
In resting human macrophages, the hexosamine signalling pathway is involved in the up-
regulation of Id1 and Id2 protein, but hyperglycaemia is not able to increase flux through the 
hexosamine signalling pathway as compared to murine macrophages and does not regulate 
GFAT and OGT protein levels. 
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Appendix 1      
Ingredients Final concentration  Ingredients Final concentration 
Glycerol  4 %  Tris/HCl  25 mM 
SDS 0.8 %  Glycine  0.2 M 
DTT 40 mM  SDS 0,1 % 
Bromophenol blue 0.025 %  Table 3 1 x Running buffer 
Tris buffer, pH 6.8 40 mM    
Table 1 1 x Loading buffer.           
  
Ingredients Final concentration  Ingredients Final concentration 
Tris/HCl, pH 7.0 50 mM  Tris/HCl 2.5 mM 
NaCl 150 mM  Glycine 20 mM 
SDS 0.1 %  Methanol 2 % 
NP-40 1 %  Table 4 1 x Towbin buffer 
Na-Deoxycholate 1 %    
EDTA 2 mM    
Tx-100 1 %    
ALLN 30 μM  Ingredients Final concentration 
AEBSF 1 mM  Tris/HCl 10 mM 
Protease inhibitors 1 tablet  NaCl 150 mM 
DTT 1 mM   Tween 20 0.05 % 
NaF 50 mM  Table 5 1 x TBS-T  
Na4PO2O7 10 mM    
N3VO4 1-2 mM    
Table 2 1 x RIPA buffer   
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Ingredients Final concentration  Ingredients Final 
concentration 
Tris, pH 7.6 100 mM  Hepes, pH 7.9 5 mM 
NaCl 100 mM  Glycerol 26 % 
MgCl2 30 mM  MgCl2 1.5 mM 
ALLN 300 μM  EDTA  0.2 mM 
AEBSF 25 μM  ALLN 3 μM 
Protease inhibitors 1 tablet  AEBSF 250 μM 
Table 6 Hypotonic buffer  Protease inhibitors 1 tablet 
   DTT 200 μM 
Table 7 Dent & Latchman buffer  
 
 
 
 
 
